|
| Tuesday, September 6, 2022 |
|
|
Oculis 宣布刊登和發表2期臨床試驗數據 突顯眼藥滴劑 OCS-01可改善糖尿病黃斑水腫患者的黃斑厚度和視力 |
| 利用突破性技術和革命性療法從而改善視力及保護眼睛的國際眼科公司Oculis S.A.（「Oculis」）宣布已在《Acta Ophthalmologica》 期刊「《ACTA》」發表2期OCS-01（DX-211）臨床試驗 more info >> |
|
|
Oculis announces publication of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema |
| Oculis S.A., ('Oculis') a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, announces that the Phase 2 DX-211, a randomized, double blinded, multi-center and vehicle controlled clinical trial assessing the safety and efficacy of topical OCS-01 in patients with Diabetic Macular Edema (DME) (NCT05343156) has been published by the Acta Ophthalmologica journal. more info >> |
|
| Tuesday, August 23, 2022 |
|
|
Oculis公佈II期數據抗腫瘤壞死因子(anti-TNFa)眼藥滴劑利卡明利單抗(OCS-02)可緩解嚴重干眼病患者的持續眼部不適 |
| 利用突破性技術和革命性療法改善視力及保護眼睛的國際眼科公司 Oculis SA(「Oculis」)宣布，通過雙盲、多中心和安慰劑對照試驗以評估外用利卡明利單抗（OCS-02）紓緩嚴重干眼病患者整體眼部不適的療效的II期臨床試驗結果(NCT02365519),已刊載於Clinical Ophthalmology期刊。完整報告請於美國國立衛生研究院(NIH)網站索取。 more info >> |
|
|
Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFa agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease |
| Oculis S.A., ('Oculis') a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, announces that the results of the double blinded more info >> |
|
| Wednesday, June 29, 2022 |
|
|
Oculis宣布首名患者參與OCS-01「OPTIMIZE」3期臨床試驗旨在治療白內障手術後炎症和疼痛 |
| 利用突破性技術和革命性療法從而改善視力及保護眼睛的國際眼科公司Oculis S.A.（Oculis），今天宣布首名患者已參與其名為「OPTIMIZE」 (Once-daily Post ocular surgery Treatment for InflaMmation and paIn to minimiZE drops) （治療眼科手術後炎症和疼痛的眼藥滴劑，每日單次使用）的3期臨床試驗 more info >> |
|
|
Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery |
| Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations more info >> |
|
| Wednesday, March 2, 2022 |
|
|
Oculis 获Accure Therapeutics授权引进用于治疗青光眼的神经保护候选药物 进一步强化集团的领先眼科产品线 |
| 利用突破性技术和革命性疗法从而改善视力及眼睛护理的国际眼科公司Oculis S.A.（Oculis），与私人转化神经科学研发公司Accure Therapeutics今天宣布达成授权协议，授予Oculis在全球开发与商业化ACT-01的独家权利。 more info >> |
|
|
Oculis獲Accure Therapeutics授權引進用於治療青光眼的神經保護候選藥物 進一步強化集團的領先眼科產品線 |
| 利用突破性技術和革命性療法從而改善視力及眼睛護理的國際眼科公司Oculis S.A.（Oculis），與私人轉化神經科學研發公司Accure Therapeutics今天宣布達成授權協議，授予Oculis在全球開發與商業化ACT-01的獨家權利。 more info >> |
|
|
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics |
| Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics, a private translational neuroscience R&D company more info >> |
|
| Tuesday, February 8, 2022 |
|
|
Oculis 任命 Bastian Dehmel 博士为首席临床开发官 |
| Oculis S.A.（“Oculis”）为一家后期临床生物医药公司，专注于开发创新性眼科治疗方法以改善患者的视力和生活。公司宣布委任 Bastian Dehmel 博士为全球首席临床开发官 more info >> |
|
|
|
|
